Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

ImmunoGen, Inc. (IMGN), AEterna Zentaris Inc. (USA) (AEZS) – Tackling Cancer: Your Best Investing Ideas

Page 1 of 2

Over the past three months, we’ve taken a deep dive into the 12 cancer types most likely to be diagnosed in the U.S. this year according to the American Cancer Society (link opens PDF file). As we’ve witnessed, public awareness of risk factors have been a big help in reducing the occurrences of some of the most prominent cancer types. But, research has also yielded more effective drugs that are helping improve the quality and length of life for cancer patients for nearly all 12 types of cancer.

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)

Today, as the wrap-up and final article in this Tackling Cancer series, I thought we’d take one final look at the top investment selections across this grouping of cancers, from both a high-risk, high-reward perspective, as well as from an established company perspective.

High-risk, high-reward suggestions
There’s an undeniably large dollar amount being pledged to cancer research, but, even if a drug gains approval, that’s no guarantee that the biotech or pharmaceutical company behind that drug will be a success. Some of the biggest gains (and losses) come from taking a leap of faith based on clinical data, or the approval of one or two drugs or devices within a pipeline. After that, it’s all up to the drug or devices’ effectiveness, its pricing, and the success of the marketing teams promoting the drug or device. Here are a few high-risk, high-reward names you should be keeping your eye on.

  • Exelixis, Inc. (NASDAQ:EXEL): In November Exelixis, Inc. (NASDAQ:EXEL) had its first drug, known as Cometriq, approved by the Food and Drug Administration to treat metastatic medullary thyroid cancer. Although the market for this disease is pretty small — somewhere between 500 and 700 people in the U.S. — the near-tripling in progression-free survival, or PFS, in trials would indicate to me a strong likelihood that it could translate to success in other cancer types. In mid-stage prostate cancer trials, for instance, Cometriq was found to be particularly effective in dealing with bone metastases as a second or third-line treatment. We won’t get any additional data until next year on Cometriq, but positive data on the prostate cancer front could be enough to double its share price if the PFS, compared to the placebo, is notably strong.
  • ImmunoGen, Inc. (NASDAQ:IMGN): In February, Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) and ImmunoGen, Inc. (NASDAQ:IMGN) received approval for Kadcyla as a secondary treatment for HER2-positive breast cancer. This is ImmunoGen, Inc. (NASDAQ:IMGN)’s first drug approval, and it gives the company a chance to showcase what I feel is one of the future pathways of fighting cancer — its targeted-antibody payload, or TAP, technology. ImmunoGen, Inc. (NASDAQ:IMGN)’s TAP technology works by attaching a toxin — in this case Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY)’s Herceptin — to an antibody, and teaching that antibody to release the toxin when it comes in contact with a protein expressed by the targeted cancer cell. Although ImmunoGen, Inc. (NASDAQ:IMGN)’s royalties on Kadcyla are lower than investors would have hoped for, it’s the additional 18 clinical trials currently under way that should have investors excited about its potential. If the 50% improvement in PFS over the placebo can be translated to even a few of these other trials, ImmunoGen, Inc. (NASDAQ:IMGN)’s share price could soar.
  • AEterna Zentaris Inc. (USA) (NASDAQ:AEZS): Bias alert! Bias alert! I own shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), but can’t help but feel that its late-stage intravenous treatment, AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) -108, for the treatment of endometrial cancer, is on its way toward an approval. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) -108, which is a targeted cytotoxic peptide conjugate (this means it targets cancer cells and leaves healthy cells intact), produced an overall response rate of 30.8% in trials with a clinical benefit rate of 74.4%, and received a special protocol assessment from the FDA. This should streamline getting AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)-108 to market if its upcoming results prove statistically significant, and would go a long way to improving AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)’s severely depressed share price.
Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!